EMA Authorised: Aimovig (erenumab) — Novartis Europharm Limited

View source ↗

Summary

EMA authorised Aimovig (erenumab) for migraine disorders. Novartis Europharm Limited is listed as the marketing authorisation holder; decision date 01/12/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• AIMOVIG (ERENUMAB-AOOE)

Snippet

Status: Authorised. Therapeutic area: Migraine Disorders. MAH: Novartis Europharm Limited. Decision date: 01/12/2025